StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Earnings

Matinas BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2024
–
EPS, Q2 FY2024
-$0.02
-$0.03 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Matinas BioPharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2024ended Jun 30, 2024Aug 14, 2024during market hours––-$0.02Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours––-$0.03Release
Q4 FY2023ended Dec 31, 2023Mar 27, 2024during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 8, 2023during market hours––-$0.03Release
Q2 FY2023ended Jun 30, 2023Aug 9, 2023during market hours––-$0.03Release
Q1 FY2023ended Mar 31, 2023May 10, 2023during market hours–––Release
Q4 FY2022ended Dec 31, 2022Mar 15, 2023during market hours–––Release
Q3 FY2022ended Sep 30, 2022Nov 2, 2022during market hours$1.10M–-$0.03Release
Q2 FY2022ended Jun 30, 2022Aug 11, 2022before the open$1.10M–-$0.03Release
Q1 FY2022ended Mar 31, 2022May 12, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 8, 2022before the open––-$0.03Release
Q3 FY2021ended Sep 30, 2021Nov 8, 2021before the open––-$0.03Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Matinas BioPharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Matinas BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Matinas BioPharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Update
  3. News
  4. News
  5. News
  6. News
  7. Update
  8. Results
  9. Results
  10. Results
  11. Update
  12. Update
  13. Results
  14. Update
  15. Update

See a number that looks wrong?